- Research article
- Open Access
Newcastle disease virus selectively infects dividing cells and promotes viral proliferation
- Zhili Chu†1, 2,
- Xiaolong Gao†1,
- Haijin Liu1,
- Jiangang Ma1,
- Caiying Wang1,
- Kejia Lu1,
- Qingsong Han1,
- Yanhong Wang1,
- Chongyang Wang1,
- Fathalrhman E. A. Adam1, 3,
- Xinglong Wang1,
- Sa Xiao1 and
- Zengqi Yang1Email author
© The Author(s) 2019
- Received: 18 November 2018
- Accepted: 23 January 2019
- Published: 18 April 2019
Newcastle disease virus (NDV) can select cells to infect, but the mechanism of its cell selectivity has not been comprehensively investigated. Here, we use HeLa cells to establish that NDV can selectively infect cells at the single-cell level. We labeled proliferating cells with 5′-bromo-2-deoxyuridine (BrdU) and examined the colocalization of BrdU with NDV in cells to clarify the relationships between NDV infection and cell proliferation. Receptors at the plasma membrane mediate NDV entry into host cells. We labeled sialic acid receptor isoforms, compared their densities between different cell types and measured the sialic acid receptor densities in different cell phases. Our results suggest that NDV displays host tropism to HeLa cells compared to BHK cells and that the differences in the receptor isoform expression patterns between cell types contribute to the selection of HeLa by NDV. At the single-cell level, the dynamics of receptor expression changes during different cell phases contributing to the selection of cells in S/G2 phase for NDV infection. Furthermore, cell proliferation benefits viral replication, and enhanced virus replication leads to increased damage to cells. The elucidation of the mechanisms underlying host cell selection by NDV may help in the screening and characterizing of additional candidate oncolytic virus strains.
Newcastle disease (ND), which is caused by the Newcastle disease virus (NDV), is one of the most severe avian diseases and can cause great economic loss to the poultry industry worldwide . ND is a contagious disease, and NDV can infect a wide range of domestic and wild birds and kinds of cells. Viruses have evolved to manipulate and take control of the programmed cell death response, but the infected cell attempts to neutralize viral infections by activating different stress signals and defensive pathways to antagonize virus-induced cell self-destruction . Both extrinsic and intrinsic apoptotic pathways can be activated in cells after NDV infection , and NDV-induced cell death predominantly occurs via apoptosis [2–5]. As an oncolytic virus, NDV is a promising agent for cancer treatment, and its lytic nature makes it effective in identifying and destroying malignant cells . In the early 1950s, NDV became a promising oncolytic agent [7, 8]. Since then, NDV has been extensively investigated for its use in cancer treatment [9–11]. In 1968, the first attenuated NDV vaccine to be systematically administrated was given to several patients with metastatic carcinoma . To date, NDV has been widely used as a cancer vaccine and an oncolytic agent in several clinical trials of certain human cancers [13–17]. NDV can selectively infect cells, but the mechanism of its cell selectivity has not been comprehensively investigated.
During viral infection, the first challenge that viruses must overcome is gaining access to the intracellular machinery, and the infection process starts when the virus interacts with a target receptor on the host cell, after which the initial steps of virus entry begin . Sialic acids (Sias) represent a family of sugar molecules, with N-acetylneuraminic acid (Neu5Ac) as the most common variant . NDV binds to the Sia receptor on host cells and can infect a broad range of cell types and this replication process kills the host cells . However, no study has specifically examined whether NDV selectively infects cells because of differences in the expression pattern of Sia receptors in different cell cycles.
The eukaryotic cell cycle is generally divided into four stages: gap 1 phase (G1), synthesis phase (S), gap 2 phase (G2), and mitotic phase (M); DNA synthesis takes place in the S phase, generating exactly two identical sister chromosomes; G2 phase is a period of rapid cell growth and protein synthesis during which cells get ready for mitosis . In sharp contrast to normal cells that only divide a finite number of times, cancer cells never cease to proliferate. Proliferation is one of the hallmarks of cancer cells, and this perhaps due to the aberrant modification in glycosylation, particularly that in terminal sialylation correlates with tumorigenic transformation and progression . The proliferation activity of cancer cells is often used as a promising therapeutic target for cancer in clinical applications. For cancer cells, it is still not entirely understood whether oncolytic viruses can target its proliferation characteristics and select proliferative cells.
In the present study, by using single-cell and mixed culture experiments, we tested the relationship among host receptors, cell proliferation and NDV selectivity. Our hypothesis was that the cell selectivity of NDV benefits its replication. Dynamic changes in the Sia receptor profile between different cell types and cell phases, along with cell proliferation status, were shown to be important factors responsible for the cell selectivity of NDV.
Animal experiments and ethics statements
The protocol in this study was approved by the Committee on the Ethics of Animal Care and Use of the National Research Center for Veterinary Medicine (Permit 20160313088). All animal works complied with the guidelines of the Animal Care and Use Committee of Northwest A&F University after prior approval.
Cell culture and virus
The HeLa and BHK-21 (BHK) cells used in this study were stored in our laboratory. BHK-RFP and HeLa-RFP cells were produced by transfecting BHK/HeLa cells with pCDH-CMV-MCS-EF1-RFP before use. All cells were maintained in DMEM (Sigma) supplemented with 10% (or 5%, 2% or 0% where indicated) fetal bovine serum (FBS), 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2 mM l-glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), and 0.1 mM β-mercaptoethanol (Sigma). The La Sota and F48E9 NDV strains were used in this study. La Sota is a standard genotype II lentogenic NDV strain, and F48E9 is a standard genotype IX NDV strain in China. These two strains were propagated in the allantoic cavity of 9- to 11-day-old SPF embryonated chicken eggs, and all allantoic fluid samples were harvested and stored at −70 °C until further use .
For cell cycle analysis, cells were harvested and washed twice with PBS. Cells were digested by trypsin for a relatively long time (5 min), until almost all cells were in a unicellular state. After rinsing, the cells were suspended and fixed with 75% ice-cold ethanol for 24 h at 4 °C. Then, the cells were centrifuged at 600 g for 10 min and washed with PBS. Finally, the cells were resuspended in 500 µL of PBS containing 50 µg/mL propidium iodide (PI), 100 µg/mL RNase (MP Biomedicals) and 0.037 mg/mL EDTA (MP Biomedicals) and incubated at 37 °C for 30 min. The prepared samples were analyzed using a FACS (FACSCalibur, BD). Apoptotic cell death was detected by the Annexin V/PI staining assay (HeYan Biotech Ltd., Shanghai) according to the manufacturer’s protocols. Briefly, cells were harvested and washed twice with PBS. Then, the cells were suspended in 400 µL of binding buffer, followed by incubation with 5 µL Annexin V per sample for 15 min. Subsequently, 10 µL of PI per sample was added, and the samples were analyzed via FACS (FACSCalibur, BD, USA). The data were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
Immunofluorescence and immunocytochemical analyses
BrdU is commonly used in studies of DNA replication and cell proliferation . To understand whether NDV selectively infects dividing cells, we labeled the cells with BrdU (5 μM) and infected the cells with the La Sota NDV strain (0.1 MOI) for 16 h (La Sota) or 12 h (F48E9). For BrdU immunofluorescence, cell samples were fixed with 4% paraformaldehyde (PFA) for 15 min. After the cells were washed three times with PBS, they were treated with 2 M hydrochloric acid in ultrapure water for 30 min at room temperature, followed by the addition of 0.2% sodium borate solution and another incubation for 30 min at room temperature. Then, the cells were blocked with 1% BSA for 30 min and then incubated with a primary antibody against BrdU (1:100 dilution; BOSHIDE, China) and a chicken polyclonal anti-NDV serum (1:500 dilution; prepared in our laboratory) overnight at 4 °C. The next day, the cells were washed three times in PBS and treated with Alexa Fluor® 488-conjugated goat anti-chicken IgY H&L (1:500 dilution; Abcam, Cambridge, UK) and Alexa Fluor 594-conjugated donkey anti-mouse secondary antibodies (1:500 dilution; Invitrogen, Carlsbad, CA, USA) for 1 h at room temperature in a dark box. Finally, nuclei were stained with Hoechst 33342 (5 µg/mL) for 5 min. Images viewed on a Leica fluorescence microscope or an Andor Revolution WD confocal microscope was captured. For quantification of the GFP/RFP ratio by flow cytometry, the cells were harvested and washed twice with PBS. Chicken polyclonal anti-NDV and mouse anti-RFP primary antibodies (1:300 dilution; Bioss; Beijing; China) were used in this experiment. Fluorescence staining was performed in a test tube, and the staining procedure was performed as previously described . In particular, to wash the cells, centrifugation was conducted five times between each step.
RNA and q-PCR
Forward primer (5′–3′)
Reverse primers (5′–3′)
NDV M gene 
NDV-specific reverse-transcription primer 
Detection of Sias by lectin staining assay
α2,3 and α2,6 N-linked Sias allow for efficient interaction of NDV with target cells . SNA binds preferentially to Sias attached to terminal galactose through the α2,6 linkage and, to a lesser degree, α2,3 linkage. MAL1 binds to Gal (β-1,4) GlcNAc but tolerates the substitution of N-acetyllactosamine with Sia at the 3 position of galactose. After harvesting, cells were fixed with 4% PFA at room temperature for 30 min. Lectin staining was performed with fluorescein-labeled Maackia amurensis lectin I (MAL1; Vector Laboratories, San Mateo, CA, USA) and Sambucus nigra lectin (SNA; Vector Laboratories, CA, USA) according to the manufacturer’s instructions. MAL1 binds to Gal (β-1,4) GlcNAc but tolerates the substitution of N-acetyllactosamine with Sia at the 3 position of galactose, while SNA binds to α2,6-linked Sia. The respective lectins were added to the cell cultures, and the samples were incubated at 37 °C for 30 min and then rinsed three times with PBS. The binding of the labeled lectins to cells was detected using flow cytometry.
Viral plaque assay
The viral titer was measured by the plaque assay. Briefly, confluent monolayers of BHK cells cultured in 24-well plates were inoculated with cell supernatants at different dilutions (0.1–10 µL per well). After adsorption for 1 h at 37 °C and 5% CO2, the liquid was aspirated, and the cells were overlaid with DMEM containing 2% FBS and 1% methyl cellulose and cultured at 37 °C and 5% CO2. After 3 to 5 days, the medium was removed, and the cells were lightly washed three times with PBS and fixed with 4% PFA for 30 min. Finally, the plaques were stained with crystal violet. Manual counting of viral plaque and data shown are mean ± SD of three independent experiments.
Western blot analysis
Proteins were extracted from transfected cells or NDV-infected cells. After the protein samples were boiled for 5 min in 5% SDS–PAGE sample loading buffer, they were separated by SDS-PAGE and transferred to a PVDF membrane for Western blotting. Briefly, the membrane was blocked with 10% skim milk for 12 h at 4 °C. Then, antibodies against BAX, Bcl2, caspase-3 and GAPDH were applied at different dilutions (BAX: 1:500 dilution; Bcl2: 1:500 dilution; caspase-3: 1:500 dilution; and GAPDH: 1:1000 dilution) to detect the proteins. After a 12-h incubation at 4 °C, the membrane was washed three times with Tris-buffered saline containing Tween-20 (TBST). Subsequently, the membrane was incubated with HRP-conjugated anti-rabbit/mouse IgG (1:3000) for 1 h at 37 °C. After four additional washes with TBST, the immunoreactive protein bands were visualized with an ECL Western blotting detection reagent (Bio-Rad), and the results were analyzed using a Tanon-410 automated gel imaging system.
The Student’s t test was used when only two groups of data were compared. All data are presented as the means and SD, and the statistical significance of differences is reported as follows: *P < 0.05; **P < 0.01; and ***P < 0.001. All data are representative of no fewer than three different experiments, and the data were analyzed using GraphPad Prism 5 software.
At the single-cell level, NDV selectively infects proliferating cells
NDV selectively infects HeLa cells rather than neuraminidase-treated HeLa cells
Despite the presence of BHK cells, NDV selectively infects HeLa cells
Select proliferating cells promote virus replication
To further elucidate whether the selection of proliferating cells by NDV benefits the virus replication, we conducted the following experiments. Given that cell proliferation requires a nutrient supply to control the rate of cell growth, we reduced the concentration of FBS in the culture medium. After incubating the cells in different culture media for 12 h, the cell proliferation index was calculated. BrdU immunofluorescence staining of those cells produced similar results: the proportion of BrdU-positive cells increased with increasing FBS concentrations (Figure 5A). Flow cytometry was used to examine the effects of serum on cell cycle progression, and the results suggest that when the FBS concentration in the culture medium was increased (to no more than 10%), the proportion of HeLa cells in G1 phase decreased (Figure 5B). This result indicates that cell proliferation can be affected by the concentration of FBS. Apoptosis is widely thought to suppress the host cell’s response to NDV replication. In the above experiment, we treated cells with different concentrations of FBS to control the growth rate, but serum starvation might lead to cell apoptosis . We detected apoptosis after changing the medium, and our results suggest that short-term treatment of the cells with medium either lacking FBS or containing a low concentration of FBS for 12 h did not lead to significant apoptosis of HeLa cells (Figure 5C). Therefore, the different replication abilities of NDV under different nutrient conditions appear not to be affected by apoptosis.
To determine the influence of cell proliferation on NDV replication, we infected HeLa cells with the La Sota NDV strain (1 MOI). At 24 hpi, real-time fluorescence q-PCR was used to measure the total viral RNA levels in cell lysates and conditioned media. Compared with the serum-free and low-FBS-supplemented groups, the control group shows higher viral RNA levels in vigorously growing cells (Figure 5D). The plaque test shows similar trends between the F48E9 and La Sota NDV strains (Figure 5E). These results suggest that NDV replication increased with increasing proportions of cells in S and G2 phase, suggesting that selective infection of NDV in dividing cells benefits NDV replication.
Increased NDV replication leads to more serious damage
For the cell selection mechanism of NDV at the single-cell level, we observed that NDV tends to infect cells in the S/G2 phase (Figure 2). To our knowledge, there are no reports about the relationship between the cell cycle and changes in Sia dynamics. Our findings suggest that cells in the S/G2 phase have a higher receptor density than do cells in the G1 phase (Figure 2), which may explain why NDV selectively infected BrdU-positive cells in single-cell cultures. No study has reported on differences in cell selectivity between different NDV strains. In our work, both the virulent F48E9 strain and the lentogenic La Sota strain selectively infected proliferating cells, but their potencies in selecting proliferating cells differed (Figures 2, 3). NDV selectively infects dividing cells in HeLa and BHK cell cultures, but the ratios were not exactly the same. Thus, we conclude that the capability of selecting S/G2 phase cells is a common characteristic of NDV that may vary according to the cell type and NDV strain. Based on this method, an evaluation system for screening of the oncolytic NDV strain may be established.
As extensively demonstrated in vitro and in accordance with a classic rule of thermodynamics, the more attachment factors or receptors that are present at the cell surface and the higher the affinity of a virus with these receptors, the more efficient the primary interaction is . It is well known that different cell types express distinct receptor types at specific quantities. In our study, NDV preferentially infected HeLa cells relative to HeLa(E) and BHK cells, and HeLa cells expressed SNA- and MAL1-labeled Sia receptors on their surface more abundantly than did HeLa(E) and BHK cells (Figures 4 and 5); this difference may be why NDV selectively infected HeLa cells. In addition, it has been reported that α2,6-linked Sia functions as a high-affinity receptor with NDV in oncolytic virotherapy . BHK cells lack α2,6-linked Sia (Figure 5A), which may be another reason NDV selected HeLa cells. Normal cells were found to be resistant to NDV replication. Therefore, we investigated the relationship between cell proliferation and viral replication. Our results suggest that cell proliferation is beneficial to viral replication (Figure 6). It has been reported that the nutrient/physical status of the host links innate immunity to antiviral host defense and that a higher nutrient status increases virus replication . In our study, we used different concentrations of FBS to regulate cell growth and found that cells with a higher proliferative ability exhibited increased virus replication. These results suggest that NDV replication may be affected by the nutrient/physical status of the host cell.
Viruses have evolved to manipulate and take control of the programmed cell death response, but the infected cell attempts to neutralize viral infections by activation of different stress signals and defensive pathways to antagonize the virus-induced cell self-destruction . The inherent anti-tumor capacity of NDV combines two characteristics that delineate what can be defined as the oncolytic paradigm: NDV promotes the induction of tumor cell death accompanied by the elicitation of antitumor immunity . Both extrinsic and intrinsic apoptotic pathways can be activated in cancer cells after NDV infection , and apoptosis dominantly contributes to NDV induced cell death [2–4, 36]. In lung cancer cells, higher virus particles infecting the cell corresponded to more cell death . In our experiments, apoptosis was more extensive in HeLa cells infected with NDV at a high MOI than in cells infected with NDV at a low MOI (Figure 6). Therefore, we conclude that NDV selects dividing cells for infection and replication, leading to apoptosis of those dividing cells. NDV has the ability to selectively kill apoptosis-resistant cells . In our study, we found that cell proliferation was not positively correlated with cell apoptosis (Figure 6), suggesting that the selection of proliferating cells by NDV is independent of apoptosis resistance. Tumor cells have a lower capacity to resist NDV replication, and another reason may be that tumor cells have a lower interferon level [39, 40] or are resistant to apoptosis . Given the limitations of materials and methods in this study, we did not measure the interferon concentration at the single-cell level. Here, we show the selectivity of NDV among the same cells in one culture dish grown in cell culture medium containing the same interferon concentration, suggesting that the selection of proliferating cells by NDV is independent of the extent of interferon resistance.
In general, our results suggest that in one cell type, NDV tends to infect cells during the S/G2 phase in the absence of interference from other cell types. Moreover, the selective infection of dividing cells by NDV benefited its replication, and enhanced NDV replication in cells with increased cell damage (Figure 6D).
The authors declare that they have no competing interests.
ZC, ZY, XG designed research. ZC, XG, JM, CW, AF, HL and KL performed research. ZC, QH, SX, XW, FA, YW, CW and ZY analyzed data. ZC and ZY wrote the paper. All authors read and approved the final manuscript.
The authors thank the instruments sharing platform in Northwest A&F University for the assistance in technical support.
This work was supported by the National Natural Science Foundation of China (No. 31572538).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Cuadrado-Castano S, Sanchez-Aparicio MT, García-Sastre A, Villar E (2015) The therapeutic effect of death: newcastle disease virus and its antitumor potential. Virus Res 209:56–66View ArticlePubMedPubMed CentralGoogle Scholar
- Elankumaran S, Rockemann D, Samal SK (2006) Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 80:7522–7534View ArticlePubMedPubMed CentralGoogle Scholar
- Bu X, Zhao Y, Zhang Z, Wang M, Li M, Yan Y (2016) Recombinant Newcastle disease virus (rL-RVG) triggers autophagy and apoptosis in gastric carcinoma cells by inducing ER stress. Am J Cancer Res 6:924–936PubMedPubMed CentralGoogle Scholar
- Ravindra PV, Tiwari AK, Ratta B, Chaturvedi U, Palia SK, Chauhan RS (2009) Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res 141:13–20View ArticlePubMedGoogle Scholar
- Ravindra PV, Tiwari AK, Sharma B, Chauhan RS (2009) Newcastle disease virus as an oncolytic agent. Indian J Med Res 130:507–513PubMedGoogle Scholar
- Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254:178–216View ArticlePubMedGoogle Scholar
- Moore AE, Diamond LC, Mackay HH, Sabachewsky L (1952) Influence of hemagglutinating viruses on tumor cell suspensions. II. Newcastle disease virus and Ehrlich carcinoma. Proc Soc Exp Biol Med 81:498–501View ArticlePubMedGoogle Scholar
- Prince AM, Ginsberg HS (1957) Studies on the cytotoxic effect of Newcastle disease virus (NDV) on Ehrlich ascites tumor cells. II. The mechanism and significance of in vitro recovery from the effect of NDV. J Immunol 79:107–112PubMedGoogle Scholar
- Harper JA, Travers J, Franks R, Burke S, Navarro C, Xing C, Wang W, Xu Q, Wilkinson RW, Jin H (2016) Abstract 2234: exploring the oncolytic potential of Newcastle Disease Virus. Cancer Res 76:2234View ArticleGoogle Scholar
- Wu Y, He J, An Y, Wang X, Liu Y, Yan S, Ye X, Qi J, Zhu S, Yu Q (2016) Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. J Pharmacol Sci 132:24–30View ArticlePubMedGoogle Scholar
- Zamarin D, Palese P (2012) Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7:347–367View ArticlePubMedPubMed CentralGoogle Scholar
- Csatary LK, Bakács T (1999) Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281:1588–1589View ArticlePubMedGoogle Scholar
- Freeman AI, Zakay-Rones Z, Gomori JM, Linetsky E, Rasooly L, Greenbaum E, Rozenman-Yair S, Panet A, Libson E, Irving CS (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221–228View ArticlePubMedGoogle Scholar
- Lorence RM, Roberts MS, O’Neil JD, Groene WS, Miller JA, Mueller SN, Bamat MK (2007) Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets 7:157–167View ArticlePubMedGoogle Scholar
- Schirrmacher V (2017) Immunobiology of Newcastle disease virus and its use for prophylactic vaccination in poultry and as adjuvant for therapeutic vaccination in cancer patients. Int J Mol Sci 18:E1103View ArticlePubMedGoogle Scholar
- Xu X, Sun Q, Yu X, Zhao L (2017) Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Res 233:35–41View ArticlePubMedGoogle Scholar
- Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O’Neil JD, Roberts MS, Groene WS, Major PP (2007) An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 13:977–985View ArticlePubMedGoogle Scholar
- Boulant S, Stanifer M, Lozach PY (2015) Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis. Viruses 7:2794–2815View ArticlePubMedPubMed CentralGoogle Scholar
- Schauer R, Fischer C, Lee H, Ruch B, Kelm S (1988) Sialic Acids as Regulators of Molecular and Cellular Interactions. Springer, Berlin HeidelbergView ArticleGoogle Scholar
- Cheng X, Wang W, Xu Q, Harper J, Carroll D, Galinski MS, Suzich J, Jin H (2016) Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 90:5343–5352View ArticlePubMedPubMed CentralGoogle Scholar
- Fan Y, Sanyal S, Bruzzone R (2018) Breaking bad: how viruses subvert the cell cycle. Front Cell Infect Microbiol 8:396View ArticlePubMedPubMed CentralGoogle Scholar
- Fuster MM, Esko JD (2005) The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 5:526–542View ArticlePubMedPubMed CentralGoogle Scholar
- Gao X, Hu X, Tong L, Liu D, Chang X, Wang H, Dang R, Wang X, Xiao S, Du E (2016) Construction of a camelid VHH yeast two-hybrid library and the selection of VHH against haemagglutinin-neuraminidase protein of the Newcastle disease virus. BMC Vet Res 12:39View ArticlePubMedPubMed CentralGoogle Scholar
- Nowakowski RS, Lewin SB, Miller MW (1989) Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J Neurocytol 18:311–318View ArticlePubMedGoogle Scholar
- Chu Z, Niu B, Zhu H, He X, Bai C, Li G, Hua J (2015) PRMT5 enhances generation of induced pluripotent stem cells from dairy goat embryonic fibroblasts via down-regulation of p53. Cell Prolif 48:29–38View ArticlePubMedGoogle Scholar
- Chu Z, Wang C, Tang Q, Shi X, Gao X, Ma J, Lu K, Han Q, Jia Y, Wang X, Adam FEA, Liu H, Xiao S, Wang X, Yang Z (2018) Newcastle disease virus V protein inhibits cell apoptosis and promotes viral replication by targeting CacyBP/SIP. Front Cell Infect Microbiol 8:304View ArticlePubMedPubMed CentralGoogle Scholar
- Sánchez-Felipe L, Villar E, Muñoz-Barroso I (2012) α2-3- and α2-6- N-linked sialic acids allow efficient interaction of Newcastle Disease Virus with target cells. Glycoconj J 29:539–549View ArticlePubMedGoogle Scholar
- Sinkovics JG, Horvath JC (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 16:1View ArticlePubMedGoogle Scholar
- Walter RJ, Attar BM, Rafiq A, Tejaswi S, Delimata M (2012) Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity. JOP 13:45–53PubMedGoogle Scholar
- Kulkarni GV, McCulloch CA (1994) Serum deprivation induces apoptotic cell death in a subset of Balb/c 3T3 fibroblasts. J Cell Sci 107:1169–1179PubMedGoogle Scholar
- Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: MarvelousIY complex. Adv Cancer Res 84:81–154View ArticlePubMedPubMed CentralGoogle Scholar
- Boulant S, Stanifer M, Lozach PY (2015) Dynamics of virus-receptor interactions in virus binding, signaling, and endocytosis. Viruses 7:2794–2815View ArticlePubMedPubMed CentralGoogle Scholar
- Li Q, Wei D, Feng F, Wang XL, Li C, Chen ZN, Bian H (2017) α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus. J Cancer Res Clin Oncol 143:2171–2181View ArticlePubMedGoogle Scholar
- Zhang Q, Meng F, Chen S, Plouffe SW, Wu S, Liu S, Li X, Zhou R, Wang J, Zhao B, Liu J, Qin J, Zou J, Feng XH, Guan KL, Xu P (2017) Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nat Cell Biol 19:362–374View ArticlePubMedPubMed CentralGoogle Scholar
- Cuadradocastano S, Ayllon J, Mansour M, de la Iglesia-Vicente J, Jordan S, Tripathi S, Garcíasastre A, Villar E (2015) Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol Cancer Ther 14:1247–1258View ArticleGoogle Scholar
- Ravindra PV, Tiwari AK, Ratta B, Bais MV, Chaturvedi U, Palia SK, Sharma B, Chauhan RS (2009) Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res 144:350–354View ArticlePubMedGoogle Scholar
- Hu L, Sun S, Wang T, Li Y, Jiang K, Lin G, Ma Y, Barr MP, Song F, Zhang G, Meng S (2015) Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am J Cancer Res 5:3612–3623PubMedPubMed CentralGoogle Scholar
- Mansour M, Palese P, Zamarin D (2011) Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 85:6015–6023View ArticlePubMedPubMed CentralGoogle Scholar
- Krishnamurthy S, Takimoto T, Scroggs RA, Portner A (2006) Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80:5145–5155View ArticlePubMedPubMed CentralGoogle Scholar
- Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK (2010) Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 84:3835–3844View ArticlePubMedPubMed CentralGoogle Scholar